237 related articles for article (PubMed ID: 33675534)
1. Norepinephrine may be an underlying factor in chemobrain.
Fitzgerald PJ
Int J Cancer; 2021 Jun; 148(12):3119-3120. PubMed ID: 33675534
[No Abstract] [Full Text] [Related]
2. Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats.
Shaker FH; El-Derany MO; Wahdan SA; El-Demerdash E; El-Mesallamy HO
Life Sci; 2021 Mar; 269():119078. PubMed ID: 33460662
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced cognitive impairment: focus on the intersection of oxidative stress and TNFα.
Rummel NG; Chaiswing L; Bondada S; St Clair DK; Butterfield DA
Cell Mol Life Sci; 2021 Oct; 78(19-20):6533-6540. PubMed ID: 34424346
[TBL] [Abstract][Full Text] [Related]
4. Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology.
Allegra A; Innao V; Basile G; Pugliese M; Allegra AG; Pulvirenti N; Musolino C
Expert Rev Hematol; 2020 Apr; 13(4):393-404. PubMed ID: 32129131
[No Abstract] [Full Text] [Related]
5. Chemotherapy-Induced Cognitive Impairment and Hippocampal Neurogenesis: A Review of Physiological Mechanisms and Interventions.
Sekeres MJ; Bradley-Garcia M; Martinez-Canabal A; Winocur G
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884513
[TBL] [Abstract][Full Text] [Related]
6. Methodological shortcomings of preclinical research on chemotherapy-induced cognitive impairment.
Ossorio-Salazar VA; D'Hooge R
Neurosci Biobehav Rev; 2023 Jul; 150():105198. PubMed ID: 37105339
[No Abstract] [Full Text] [Related]
7. Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer.
Chiaravalloti A; Filippi L; Pagani M; Schillaci O
J Nucl Med; 2023 Apr; 64(4):508-514. PubMed ID: 36732056
[TBL] [Abstract][Full Text] [Related]
8. Polydatin ameliorates chemotherapy-induced cognitive impairment (chemobrain) by inhibiting oxidative stress, inflammatory response, and apoptosis in rats.
Tong Y; Wang K; Sheng S; Cui J
Biosci Biotechnol Biochem; 2020 Jun; 84(6):1201-1210. PubMed ID: 31992173
[TBL] [Abstract][Full Text] [Related]
9. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants.
Das A; Ranadive N; Kinra M; Nampoothiri M; Arora D; Mudgal J
Curr Neuropharmacol; 2020; 18(9):838-851. PubMed ID: 32091339
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of anti-inflammatory agents in reducing chemotherapy-induced cognitive impairment in preclinical models - A systematic review.
Haller OJ; Semendric I; George RP; Collins-Praino LE; Whittaker AL
Neurosci Biobehav Rev; 2023 May; 148():105120. PubMed ID: 36906244
[TBL] [Abstract][Full Text] [Related]
11. Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions.
Skurlova M; Holubova K; Kleteckova L; Kozak T; Kubova H; Horacek J; Vales K
Med Res Rev; 2024 Jan; 44(1):5-22. PubMed ID: 37265248
[TBL] [Abstract][Full Text] [Related]
12. Norepinephrine depleting and antihypertensive effect of 4-methoxy-3,5-dihydroxyphenylalanine.
Thoenen H; Gerold M; Haefely W; Huerlimann A
Experientia; 1968 Feb; 24(2):158-9. PubMed ID: 4384506
[No Abstract] [Full Text] [Related]
13. Studies on the action of guanethidine on the central nervous system and on the norepinephrine content of the brain.
PFEIFER AK; VIZI ES; SATORY E
Biochem Pharmacol; 1962; 11():397-8. PubMed ID: 14486117
[No Abstract] [Full Text] [Related]
14. The action of drugs on the noradrenaline content of brain and sympathetic ganglia.
SANAN S; VOGT M
AFOSR TN United States Air Force Off Sci Res; 1960 Aug; 60(1286):1-8. PubMed ID: 24545752
[No Abstract] [Full Text] [Related]
15. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases.
Nguyen LD; Ehrlich BE
EMBO Mol Med; 2020 Jun; 12(6):e12075. PubMed ID: 32346964
[TBL] [Abstract][Full Text] [Related]
16. Impaired brain dopamine transporter in chemobrain patients submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1.
Vitor T; Kozasa EH; Bressan RA; Lacerda SS; Campos Neto GC; Batista IR; Gebrim LH; Cohen L; Amaro E; Felicio AC
Ann Nucl Med; 2019 Apr; 33(4):269-279. PubMed ID: 30843155
[TBL] [Abstract][Full Text] [Related]
17. [What's new concerning the chemobrain?].
Taillia H
Rev Neurol (Paris); 2013 Mar; 169(3):216-22. PubMed ID: 23107881
[TBL] [Abstract][Full Text] [Related]
18. Proceedings: BRL 13776: a novel antihypertensive agent with interesting noradrenaline-depleting properties.
Melrose J; Palfreyman MG; Poyser RH; Whiting RL
Br J Pharmacol; 1976 Mar; 56(3):361P. PubMed ID: 1260193
[No Abstract] [Full Text] [Related]
19. Neuroimmune reactivity marker expression in rodent models of chemotherapy-induced cognitive impairment: A systematic scoping review.
George RP; Semendric I; Hutchinson MR; Whittaker AL
Brain Behav Immun; 2021 May; 94():392-409. PubMed ID: 33516919
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-Induced Cognitive Impairment.
Kinsley K; Pritchett W
Clin J Oncol Nurs; 2023 Mar; 27(2):205-208. PubMed ID: 37677835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
